Among adults with type 2 diabetes receiving long-acting insulin with a glycated hemoglobin A1c level of 6.8% to 8.5%, is there a difference in cardiovascular events and mortality among individuals who do or do not initiate additional treatment with short-acting insulin? The gene discussed is INS; the disease is type 2 diabetes mellitus.